Arctoris Featured in Labiotech: Automating Cancer Research
Arctoris was featured in a Labiotech article exploring how automation technologies are transforming cancer research. The piece highlights how robotic laboratories and digital experiment management platforms can help researchers conduct complex biological experiments more efficiently. The article describes Arctoris’ vision of enabling scientists to run experiments remotely through an automated research platform. Researchers can configure…
Read MoreArctoris Featured in Nanalyze: Life Sciences Laboratory Automation
Arctoris was featured in an article by Nanalyze examining the growing role of automation in life sciences laboratories. The piece explores how robotic experimentation and automated laboratory platforms are transforming drug discovery by enabling faster, more reproducible research. As pharmaceutical R&D becomes increasingly data-driven, laboratory automation allows scientists to run experiments at greater scale and…
Read MoreHigh-Throughput Transcriptomics for Scalable Phenotypic Screening – Alithea Genomics Collaboration
Scalable drug discovery demands phenotypic data that is both mechanistically rich and compatible with high-throughput, AI/ML-driven analysis, yet conventional RNA-seq workflows remain difficult to scale…
Read More310.ai and Arctoris Partner to Pioneer AI-Designed Proteins for Cardiac Therapy
What if AI could design a brand-new protein, from scratch, to tackle heart disease? That’s no longer science fiction. In a breakthrough collaboration, 310.ai and Arctoris have validated the first de novo protein from 310’s MP4 platform that binds ATP – a critical step towards restoring energy in failing hearts. Targeting the Root Cause of Heart Failure Heart failure affects over…
Read MoreCombining Mechanistic Enzymology, Precision Biochemical Experimentation and Simulation in Drug Discovery
Integrating mechanistic enzymology with precision experimentation techniques and streamlined data simulation capabilities brings new levels of detailed understanding to the field of drug discovery and enables the comprehensive characterisation of the modes by which enzyme activators and inhibitors exert their effects. By integrating mechanistic enzymology with precision experimentation techniques and streamlined data simulation, we can…
Read MoreMacrocycles! The next chapter in small molecule drug discovery?
The Therapeutic Potential of Macrocycles in Drug Discovery Structural and Conformational Properties: Macrocycles exhibit distinct physicochemical characteristics that differentiate them from conventional small molecules. Their cyclic architectures confer a degree of conformational rigidity while maintaining three-dimensional complexity. This combination enables well-defined interactions with biological targets. As a result, macrocycles often demonstrate high binding affinity and…
Read MoreWhy Kinetics Matter
Kinetic analysis plays a central role in drug discovery by characterising the temporal aspects of drug–target interactions. These studies provide quantitative insight into binding and dissociation processes, informing key pharmacological properties such as potency, selectivity, and duration of action. Predicting drug efficacy: Kinetics can help predict how quickly a drug will bind to its target…
Read MoreBiotech 3.0: Data as the Catalyst for the Next Revolution in Drug Discovery
The integration of machine learning (ML) into small-molecule drug discovery has long been heralded as the game-changer that would bring about rapid advancements in the development of new therapeutics. Despite significant investments and the creation of increasingly sophisticated models, the substantial improvements in efficiency and anticipated outcomes have yet to materialise. The reasons for this,…
Read MoreBuilding the Future of Drug Discovery
Foundation Models and the Power of Proprietary Experimental Data In recent years, foundation models have revolutionised fields from natural language processing to image generation. Now, these powerful AI systems are transforming drug discovery. By learning generalisable patterns across chemical and biological data, foundation models are unlocking new opportunities to identify novel small molecules and biologics,…
Read MoreArctoris’ automated platform accelerates drug discovery
Oxford-headquartered Arctoris progresses programmes from target to hit, lead, and candidate with superior efficiency, accuracy, and confidence. Key to the company’s capabilities is the unique combination of robotics and data science, enabling better data to be generated faster and better decisions made earlier. Drug discovery is a series of decisions – which Target to focus on, which hit to progress,…
Read More